Mode
Text Size
Log in / Sign up

Allergy & Immunology

345 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Updated PIRCHE-T2 model improves dnDSA risk stratification in kidney transplant recipients
Allergy & Immunology Cohort
Updated PIRCHE-T2 model improves dnDSA risk stratification in kidney transplant recipients New Tool Predicts Kidney Rejection Risk With More Accuracy
This observational cohort study in 1581 kidney transplant recipients from Zurich and Basel found that an updated PIRCHE-T2 model improved de…
A smarter computer model helps doctors choose safer kidney donors.
CSF Cytokine Panel and Machine Learning for Neurosyphilis Progression Prediction
Allergy & Immunology Cohort
CSF Cytokine Panel and Machine Learning for Neurosyphilis Progression Prediction New Test Could Catch Dangerous Syphilis Complication Early
This observational cohort study evaluated 48 cerebrospinal fluid cytokines in 129 patients with syphilis to distinguish patients from contro…
Imagine getting treated for syphilis — but months later, you start forgetting things, losing balance, or going blind.
Transcriptomic signature distinguishes MASL from MASH using neural network model
Allergy & Immunology Cohort
Transcriptomic signature distinguishes MASL from MASH using neural network model New Blood Test Could Spot Hidden Liver Damage Before It’s Too Late
This observational study combined transcriptomic and single-cell analysis with an artificial neural network to differentiate metabolic dysfu…
This research could finally give doctors a simple blood test to tell the difference between harmless fat buildup and dangerous liver scarrin…
Pilot study reports 60.0% conversion rate with lenvatinib, envafolimab, and TACE in hepatocellular carcinoma.
Allergy & Immunology Cohort
Pilot study reports 60.0% conversion rate with lenvatinib, envafolimab, and TACE in hepatocellular carcinoma. New Liver Cancer Combo Makes Surgery Possible for More Patients
This prospective pilot study enrolled 15 patients with Barcelona Clinic Liver Cancer stage B or C unresectable hepatocellular carcinoma. The…
This new treatment plan turns advanced liver cancer into operable disease for many patients.
Ruxolitinib plus photopheresis shows promise for steroid-refractory chronic graft-versus-host disease
Allergy & Immunology Cohort
Ruxolitinib plus photopheresis shows promise for steroid-refractory chronic graft-versus-host disease New Hope for Stubborn Transplant Complication
A retrospective analysis compared ruxolitinib plus extracorporeal photopheresis versus photopheresis alone in patients with steroid-refracto…
This combo may help patients reduce or stop steroid use — a major win for quality of life.
Review of tissue-resident memory T cell features in cancer and autoimmune diseases
Allergy & Immunology Sys. Review
Review of tissue-resident memory T cell features in cancer and autoimmune diseases New Immune Cells Could Flip Cancer and Autoimmune Treatment
This narrative review examines the developmental differentiation and molecular features of tissue-resident memory T cells within the tumor m…
The same immune cells that help fight cancer tumors can also drive autoimmune disease damage, offering a new way to treat both conditions.
Narrative review explores cytoskeleton-mediated autophagy regulation in neurodegeneration and aging
Allergy & Immunology Sys. Review
Narrative review explores cytoskeleton-mediated autophagy regulation in neurodegeneration and aging Review suggests cytoskeleton-autophagy axis may help treat neurodegeneration and aging
This narrative review examines the role of cytoskeleton-mediated autophagy regulation in the contexts of neurodegeneration and aging. The au…
Targeting the cell's structural framework and cleanup system could offer new ways to treat neurodegeneration and aging.
First Report of Vedolizumab-Associated Recall Urticaria in a Case Report and Literature Review
Allergy & Immunology Sys. Review
First Report of Vedolizumab-Associated Recall Urticaria in a Case Report and Literature Review Why Hives Return to Old Injection Spots
This case report and literature review describes the first documented instance of vedolizumab-associated recall urticaria in a 25-year-old m…
A new case report reveals a rare skin reaction where hives return strictly to past injection sites.
Single-center retrospective study associates ferritin and eosinophil levels with acute asthma exacerbation in children
Allergy & Immunology Cohort
Single-center retrospective study associates ferritin and eosinophil levels with acute asthma exacerbation in children High Iron Levels Signal Worse Asthma Attacks in Kids
This single-center retrospective study examined 120 children with asthma to identify markers associated with acute exacerbation. Results sho…
Checking iron levels alongside standard asthma markers could help doctors predict dangerous flare-ups sooner.
Benralizumab reduces asthma exacerbations in severe eosinophilic asthma patients over 24 weeks.
Allergy & Immunology Cohort
Benralizumab reduces asthma exacerbations in severe eosinophilic asthma patients over 24 weeks. New Asthma Shot May Cut Severe Attacks to Zero
This prospective, single-arm, multicenter, phase IV study evaluated benralizumab in 138 benralizumab-naïve adults (18–75 years) with severe …
A new injection appears safe and effective at reducing severe asthma attacks in adults.
Imiquimod TLR7 stimulation shows sex-specific immune responses in HIV and non-HIV populations
Allergy & Immunology Cohort
Imiquimod TLR7 stimulation shows sex-specific immune responses in HIV and non-HIV populations Research shows immune reactions to imiquimod vary between men and women with HIV
This cohort study evaluated TLR7 stimulation with imiquimod in 1,326 individuals living with HIV and 43 people without HIV. Women living wit…
Women with HIV show different immune reactions to imiquimod than men, suggesting doctors may need to consider biological sex when developing…
Phase 1 trial shows ESAT6-MPT64 skin test safe with high sensitivity for active TB
Allergy & Immunology Cohort
Phase 1 trial shows ESAT6-MPT64 skin test safe with high sensitivity for active TB New TB Skin Test Shows Promise in Early Human Trial
A Phase 1 randomized clinical trial in 60 participants (30 healthy controls, 30 active TB patients) found the recombinant ESAT6-MPT64 skin t…
A new skin test for tuberculosis proved safe and accurately identified active cases in the first human trial, offering a simpler, cheaper al…